Business
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it exhibited at the 19th Annual St. Gallen Breast Cancer Conference in Vienna, Austria from March 12 – 15, 2025. Six studies of ProSense® in breast cancer were accepted as peer-reviewed abstracts, presented as e-posters during the conference, and are being pub
About this update from Icecure Medical Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"IceCure exhibited at the prestigious event in Vienna, Austria attended by oncologists, breast surgeons","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"An abstract on ICE3 study results by Dr. Richard Fine was accepted and included in the poster presentation gallery","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"An independent study by Dr. Ava Kwong evaluated expanding the ICE3 study population to include triple negative breast cancer and younger patients","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Four additional independent abstracts were presented at the conference and all six will be published in the scientific journal—The Breast","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":498,"olType":false},{"type":"text","content":"CAESAREA, Israel, March 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it exhibited at the 19th Annual St. Gallen Breast Cancer Conference in Vienna, Austria from March 12 – 15, 2025. Six studies of ProSense® in breast cancer were accepted as peer-reviewed abstracts, presented as e-posters during the conference, and are being published in the scientific journal, The Breast after the conference.","length":660,"tagName":"p"},{"type":"image","alt":"IceCure Medical Logo","displaySize":"","headline":null,"caption":"IceCure Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2XUcwzAVdZCf5Oz2LQaIEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc","width":400,"height":200}}},{"type":"text","content":""ProSense® received a high level of interest at this prestigious breast cancer conference in Europe where our cryoablation system is gaining increasing commercial traction driven by regulatory approval and a growing body of efficacy and safety data from third party studies," IceC...